COMPLETE LV SYSTOLIC FUNCTION RECOVERY WITH CORTICOSTEROIDS AFTER IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS

Immune checkpoint inhibitors (ICI) have transformed the treatment of several cancers by releasing restrained antitumor immune responses, but high-grade, immune-related adverse events (ir-AE) can occur, particularly with combination immunotherapy. Although the incidence of myocarditis is relatively